11 Amendments of Tiemo WÖLKEN related to 2024/2030(DEC)
Amendment 16 #
Draft opinion
Paragraph 3
Paragraph 3
3. Welcomes the continued development of the One Health Framework and the creation of the One Health Task Force to strengthen collaboration with EMA, EFSA, EEA and ECHA; considers these important steps to further strengthen the One Health approach ensuring the inclusion of human, animal and plant health, as well as their interactions with the environment; highlights the importance of ensuring good and fair cooperation between the Agencies;
Amendment 27 #
Draft opinion
Paragraph 1
Paragraph 1
1. Acknowledges that the ECHA is key in implementing a growing number of Union legislation that regulates chemicals for the benefit of protecting public health and the environment, as well as for innovation and competitiveness; recognises that the ECHA collects, evaluates and disseminates a vast amount of information on chemicals, helps companies comply with legislation and promotes the safe use of chemicals;
Amendment 30 #
Draft opinion
Paragraph 2
Paragraph 2
2. Observes that the Agenciey's budget relies on collected fees and a contribution from the Union’s general budget; highlights the need to ensure full transparency of collected fees; takes note with concern that after a rise in 2022, in 2023 the ECHA’s fee income has again decreased, increasing the reliance on the Union to finance its operations; stresses the need to address the lack of predictability of the ECHA’s fee income and reiterates its previous calls to the Commission to improve the ECHA’s budgetary certainty by presenting its proposal to strengthen the governance of ECHA in line with its commitment expressed in the Chemicals Strategy for Sustainability;
Amendment 36 #
Draft opinion
Paragraph 4
Paragraph 4
4. Acknowledges that in 2023 the ECHA delivered its regulatory tasks under the Union chemicals legislation, in particular REACH and CLP, provided scientific-technical support to the Commission in the implementation of the Chemicals Strategy for Sustainability, as well as preparing and starting work on the implementation of new regulatory tasks under the Drinking Water Directive, the Batteries Regulation and the Serious Cross- Border Threadts to Health Regulation;
Amendment 48 #
Draft opinion
Paragraph 1
Paragraph 1
1. Stresses that the EEA provides sound, independent and up-to-date scientific information on the environment; commends the quality of its outputs released in 2023, such as Pathways towards circular plastics in Europe — good practice examples from countries, business and citizens, Assessing the costs and benefits of climate change adaptation and European forest ecosystems: key allies in sustainable development;
Amendment 59 #
Draft opinion
Paragraph 6
Paragraph 6
6. Takes note with concern that despite the multi-year nature of the EEA’s tasks, an imbalance exists concerning the numbers of permanent versus contractual posts in the Agency, as well as operational staff versus support staff, leading to a constant need for reskilling as well as an overload of administrative work for scientists; considers that taking into account the substantial increase of workload, and in order to properly perform the tasks onrequired tasks linked to the Union’s goals for, inter alia, climate neutrality, circular economy and nature restoration, the EEA’s staff number should continue to substantially grow in the years to come and this should be reflected in the financial resources allocated to the Agency.
Amendment 71 #
Draft opinion
Paragraph 3
Paragraph 3
3. Notes that the EFSA closed 660 scientific questions in 2023, slightly below the target of 673 but better than the result achieved since 2020; highlights the need to decrease the amount of questions in stock; welcomes the measures put in pleasace to increase the speed of the Risk Assessment process;
Amendment 73 #
Draft opinion
Paragraph 4
Paragraph 4
4. Takes noteNotes with concern that, according to the Annual Strategy Survey launched by the EFSA asking for feedback from its customers, partners, and stakeholders who are directly or indirectly involved in the delivery of the EFSA’s scientific opinions, the EFSA’s ability to provide its advice in a timely manner remains a point of attention as in the previous year; calls on the EFSA to implement the necessary measures to improve this aspect;
Amendment 76 #
Draft opinion
Paragraph 5
Paragraph 5
5. Highlights the need for the EFSA to develop strong cooperation with all its stakeholders, including the other Agencies for better connection and outputs dissemination; welcomes the fact that the EFSA developed cooperation with Member States, including with the increased support of fthe Focal pPoints Network, mainly focusing on support in the area of data collection and communication;
Amendment 84 #
Draft opinion
Paragraph 6
Paragraph 6
6. Welcomes the fact that the EFSA continued implementing its new organisational structure that was put in place in 2022 to reflect the Transparency Regulation; highlights the need to continuously improve efficiency and transparency in the EFSA’s process architecture.
Amendment 97 #
Draft opinion
Paragraph 5
Paragraph 5
5. Recalls that the EMA is a fee- funded agency, with 88,21 % of its 2023 revenue stemming from fees for applications for marketing licenses for pharmaceutical products and for post- authorisation activities, 11,43 % stemming from the Union budget and 0,36 % from various other sources; highlights the need to ensure full transparency of these revenues and welcomes the fact that in the future the EMA will have the obligation to publish in its activity report the annual revenue received per type of fee and charge according to Regulation (EU) 2024/5682 ; _________________ 2 Regulation (EU) 2024/568 of the European Parliament and of the Council of 7 February 2024 on fees and charges payable to the European Medicines Agency, amending Regulations (EU) 2017/745 and (EU) 2022/123 of the European Parliament and of the Council and repealing Regulation (EU) No 658/2014 of the European Parliament and of the Council and Council Regulation (EC) No 297/95 (OJ L, 2024/568, 14.2.2024, ELI: http://data.europa.eu/eli/reg/2024/568/oj).